Biomedical Science | Medical XPRT

Articles & Whitepapers

Top 5 challenges facing OBGYNs

Although clinicians aim to provide the best service possible, OBGYNs worldwide continue to face widespread obstacles in delivering treatment. We spoke with international experts to hear their input on the five biggest challenges facing OBGYNs around the world. Fear of treatment and diagnosis For many women, psychological factors, such as fear of painful tests and anxiety of diagnosis, play a ...

Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d

Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity Bispecific antibodies that target tumors by engaging innate-like T cell subsets with ...

Getting Together: How GE`s Health Innovation Village Used Tech to Help Seniors During the Pandemic

How Medical Studies are Changing the World

The Second Affiliated Hospital of Nanjing Medical University Department of Pediatrics - Case Study

News

Creative Biolabs Upgrades Oncolytic Virus Product List for Immunotherapy Research

As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to ...

Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research

Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center

Exosome Services at Creative Biolabs to Accelerate Lung Cancer Research

Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society

Equipment & Solutions

Showcase

Investigational Drug (VEGFR TKI)

FOTIVDA (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.1,2 AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA in March 2021 for the treatment of adult patients ...